

# Application of Microarrays in Process Analytical Technologies

## A first step towards real time product release

### Summary


Full implementation of **Process Analytical Technologies (PAT)** in a biopharmaceutical process makes real time product release feasible.<sup>1</sup>

On line process monitoring with **near infrared (nIR) spectroscopy** gives insight in product quality as it is formed.


Extensive process understanding is necessary to identify **critical quality attributes**. By monitoring these attributes with nIR, real time quality assurance and ultimately **real time product release** can be achieved.

Application of **microarrays** during process development helps to gain insight in biological processes involved in **product formation**, increasing **process understanding**.


The NVI is working on the **implementation** of this approach on the **cultivation process step** for the manufacturing of a whole cell vaccine against whooping cough disease, caused by the *Bordetella pertussis* bacterium.



**Figure 1.** Microarray analysis on samples from five *B. pertussis* bioreactor cultivations with identical growth conditions. Samples were taken at the end of the cultivations. These cultivations are also included in figure 2. mRNA-expression levels at the end of each cultivation were plotted per gene (x-axis) against the expression levels of the common reference, a mixture of mRNA from all five cultivations (y-axis). Differences in mRNA-expression result in a deviation from the red line (x=y). Cultivation PAB0007 shows the broadest scatter pattern. In the lower right panel, a selection of genes is presented that are either up or downregulated in this cultivation.



**Figure 2.** Near-infrared analysis of seven *B. pertussis* bioreactor cultivations with identical growth conditions. The **critical quality attributes** of each cultivation (y-axis) are plotted against time (x-axis). Statistical models (PCA, PLS analysis) were used to reduce the complex near-infrared spectrum to a single dot per time unit. The red lines indicates +/- 2 standard deviations.



**Figure 3.** Schematic representation of the *B. pertussis* bacterial cell (the causative agent of whooping cough disease) and its most important virulence factors. All important virulence factors are regulated by the *bordetella virulence genes*-operon (*bvg*-operon) which is sensitive to environmental changes. Small disturbances during cultivation can switch off the *bvg*-operon, resulting in loss of protection inducing antigens on the cell surface. This severely compromises product quality.<sup>1</sup>

### Conclusions

Near-infrared (nIR) monitoring shows clear **disturbances** at 60 minutes for PAB0003 and at 400 minutes for PAB0007 compared to other cultivations (figure 2). Both peaks coincide with **oxygen limitation** (dissolved oxygen <5% for 15 minutes). nIR monitoring provides online insight in how a process evolves compared to historical data

PAB0007 shows a **broader scatter pattern** in microarray analysis (figure 1), indicating a variation in gene expression. The genes involved indicate stress and a reduction in cellular activity. The effects of an oxygen limitation at the **beginning** of the cultivation have an effect on the mRNA expression levels at the **end** of the cultivation

**Correlation** between nIR monitoring data and microarray data during process development results in extensive **process understanding**. This is necessary to address problems associated with scale up and process optimisation.

Historical data can be combined and aligned to form a **'golden reference'**. This reference defines the **boundaries** within which product quality is assured. Online nIR data analysis allows **real time quality assurance** and ultimately **real time product release**.

### Acknowledgements

We would like to thank Ingrid Maes and co-workers from Siemens Pharma Group (Zwijndrecht, Belgium) for their work on near-infrared data analysis.

### Reference List

<sup>2</sup>Guidance for Industry: PAT - a Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance. <http://www.fda.gov>.

<sup>1</sup>Locht, Antoine and Jacob-Dubuisson, Bordetella pertussis, molecular pathogenesis under multiple aspects. *Current Opinion in Microbiology* 2001, 4:82-89.